Core Insights - Amarin Corporation has transitioned to a fully partnered commercialization model across all international markets, which is expected to enhance its operational efficiency and market reach [1][3] - The Q3 2025 financial results indicate a positive trend with a 17% increase in total net revenue compared to Q3 2024, driven primarily by strong U.S. sales [4][6] - The company aims to achieve sustainable positive free cash flow by 2026, reflecting confidence in its strategic actions and operational improvements [1][4] Financial Performance - Total net revenue for Q3 2025 was $49.7 million, up from $42.3 million in Q3 2024, marking a 17% increase [4][6] - Product revenue, net increased by 16% to $48.6 million, primarily due to higher U.S. sales, which rose by 34% to $40.9 million [5][7] - Operating expenses decreased by 20% to $33.3 million, largely due to a restructuring plan implemented in June 2025 [9][12] Operating Metrics - The operating loss for Q3 2025 was $11.1 million, significantly improved from a loss of $25.2 million in Q3 2024, reflecting a 56% reduction [4][14] - The net loss for Q3 2025 was $7.7 million, compared to a net loss of $25.1 million in the same quarter of the previous year, indicating a 69% improvement [15][34] - Cash and investments at the end of Q3 2025 totaled $286.6 million, down from $305.7 million in Q3 2024 [15] Strategic Initiatives - The company has established partnerships with seven parties across nearly 100 countries to leverage regional expertise and infrastructure for the commercialization of VASCEPA/VAZKEPA [3][17] - Amarin is focused on enhancing shareholder value through strategic actions and is optimistic about its global business potential [3][4]

Core Points - Reeflex Solutions Inc. has successfully continued its operations from Ontario to Alberta under the Business Corporations Act (Alberta) [1] - Shareholders approved the continuance during the Annual and Special Meeting held on August 29, 2025 [1] - The company has updated its articles and bylaws in accordance with the ABCA, while the CUSIP/ISIN numbers and stock symbol remain unchanged [2] - The TSX Venture Exchange has granted final approval for the continuance [2] Company Overview - Reeflex Solutions Inc. is a Canadian company providing advanced engineering and manufacturing solutions across various sectors [3] - The company operates through its subsidiary, Coil Solutions Inc., which offers coiled tubing injectors and downhole tools for the oil and gas industry [3] - The manufacturing division, Ranglar Manufacturing, specializes in custom-designed mobile equipment for diverse industrial applications [3]

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- eToro, the trading and investing platform, announced that it is bringing its patented CopyTrader™ technology to US users. From today, US users have the ability to instantly copy the investment strategies of real US traders across stocks, ETFs, or cryptoassets. “We are excited to bring one of eToro’s most recognized features to the world’s largest retail investing market. CopyTrader enables millions worldwide to replicate the trades of other investors and now Ameri ...

TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. ("ThreeD" or the "Company") (CSE:IDK) (OTCQX:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to congratulate HyperCycle on its recent announcement regarding the establishment of a $1.1 billion joint venture with a consortium of South Korean investors led by Addeep Inc. The joint venture aims to establish Seoul as a central hub ...

CHICAGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the third quarter ended September 30, 2025, which were prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). Third Quarter 2025 Financial Highlights For the Three Months Ended,($ in thousands)September 30, 2025 June 30, 2025 September 30, 2024Revenues, net of Discounts ...

LONDON and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma, will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria. BIO-Europe, one of the largest and most imp ...

Core Viewpoint - Playboy, Inc. will release its third quarter financial results on November 12, 2025, and will host a conference call to discuss these results and other company information [1]. Group 1: Financial Results Announcement - The financial results for the third quarter of 2025 will be released after the U.S. stock market closes on November 12, 2025 [1]. - A conference call and audio webcast will take place on the same day at 5 p.m. Eastern Standard Time to discuss the results [1]. Group 2: Shareholder Engagement - Playboy will accept questions from shareholders, which will be addressed during the conference call [3]. - Shareholders are encouraged to submit their questions by November 7, 2025, to be considered for the call [3]. Group 3: Company Overview - Playboy, Inc. is a global pleasure and leisure company with a mission to create a culture where all people can pursue pleasure [4]. - The brand is recognized worldwide, with products and content available in approximately 180 countries [4].

Core Insights - Advent Technologies Holdings, Inc. is advancing the electrification of aviation through high-temperature proton exchange membrane fuel cells (HT-PEM FCs) in collaboration with aerospace partners [1][2] - The company’s proprietary Ion Pair™ membrane electrode assembly (MEA) enhances power output and thermal management efficiency, crucial for sustainable aviation [2][5] - Advent's HT-PEM technology allows for lighter and more compact aircraft designs, leading to improved performance and reduced operational costs [3][6] Company Overview - Advent Technologies is a leader in fuel cell and hydrogen technology, headquartered in Livermore, California, with a focus on renewable energy applications [1][6] - The company holds approximately 70 patents related to fuel cell technology, enabling high-temperature operations suitable for various sectors including aviation [6] Industry Context - Over 100 companies are engaged in developing electric flight solutions, with Advent providing essential technology for hydrogen-powered flight [2] - Stralis Aircraft, a partner of Advent, is pioneering hydrogen-powered fixed-wing aircraft, emphasizing the importance of advanced cooling systems for electric flight [3][4] - Liquid hydrogen offers a significant energy density advantage (approximately 33.3 kWh/kg) over lithium-ion batteries (around 0.3 kWh/kg), making it more suitable for long-range aviation applications [4]

Core Viewpoint - Beyond Meat has successfully completed an exchange offer for its existing 0% Convertible Senior Notes due 2027, allowing holders to exchange these notes for new 7.00% Convertible Senior Secured Second Lien PIK Toggle Notes due 2030 and shares of common stock, significantly reducing its outstanding debt and enhancing its capital structure [1][2][4]. Group 1: Exchange Offer Details - The exchange offer included up to $202.5 million in new convertible notes and up to 326,190,370 shares of common stock [1]. - As of the Early Tender Date on October 10, 2025, $1,114,603,000 in existing convertible notes were validly tendered [2]. - An additional $2,738,000 in existing convertible notes were tendered between the Early Tender Date and the Expiration Deadline on October 28, 2025 [3]. Group 2: Settlement Information - Early settlement occurred on October 15, 2025, with $208,717,000 in new convertible notes and 316,150,176 new shares issued [4]. - Following the final settlement on October 30, 2025, a total of $209,176,000 in new convertible notes and 316,926,786 new shares will have been issued [4]. - The total amount of tendered notes represents 97.16% of the outstanding principal amount of existing convertible notes, leaving $32,659,000 remaining [4]. Group 3: Eligibility and Regulatory Information - The new convertible notes and shares are offered only to "qualified institutional buyers" and "accredited investors" who own a minimum of $200,000 in existing convertible notes [5]. - The new convertible notes and shares have not been registered under the Securities Act of 1933, and the offer is not a solicitation to buy or sell any securities [6]. Group 4: Company Overview - Beyond Meat is a leading plant-based meat company focused on providing products made from simple ingredients without GMOs, hormones, or antibiotics [7]. - The company aims to replicate the taste and texture of animal-based meat while promoting health and environmental sustainability [7].

Core Insights - Seres Therapeutics has received up to $3.6 million in non-dilutive funding from CARB-X to support the development of an oral liquid formulation of SER-155, aimed at improving access for medically vulnerable patients, particularly those in intensive care who cannot take oral capsules [1][3][5] - SER-155 is being developed for patients undergoing allogeneic hematopoietic stem cell transplants (allo-HSCT) and has shown a 77% reduction in bacterial bloodstream infections (BSIs) compared to placebo in a Phase 1b study [2][5] - The development of a liquid formulation is expected to broaden the impact of SER-155 in additional high-risk patient populations susceptible to BSIs and antimicrobial resistant infections [3][5] Funding and Support - CARB-X, a global non-profit partnership, is providing funding to accelerate the development of antibacterial products, specifically targeting drug-resistant bacteria [1][4] - The funding is supported by various federal and international health organizations, including the U.S. Department of Health and Human Services and the UK Department of Health and Social Care [3][4] Clinical Development - SER-155 has received Breakthrough Therapy designation and Fast Track designation from the FDA, indicating its potential to significantly reduce the risk of infections in allo-HSCT patients [5][6] - The company is finalizing the clinical protocol for a well-powered, placebo-controlled Phase 2 study following positive feedback from the FDA [2][5] Company Background - Seres Therapeutics is focused on improving outcomes for medically vulnerable populations through live biotherapeutics and has previously developed VOWST™, the first FDA-approved orally administered microbiome therapeutic [5][6] - The company aims to evaluate SER-155 in various patient populations, including those undergoing autologous-HSCT, cancer patients with neutropenia, and patients in intensive care [6]